Pre-Eclampsia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pre-Eclampsia - Pipeline Review, H1 2016', provides an overview of the Pre-Eclampsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia - The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects - The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pre-Eclampsia Overview 6 Therapeutics Development 7 Pipeline Products for Pre-Eclampsia - Overview 7 Pre-Eclampsia - Therapeutics under Development by Companies 8 Pre-Eclampsia - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Pre-Eclampsia - Products under Development by Companies 12 Pre-Eclampsia - Companies Involved in Therapeutics Development 13 A1M Pharma AB 13 Alnylam Pharmaceuticals, Inc. 14 Glenveigh Medical, LLC 15 Pluristem Therapeutics Inc. 16 rEVO Biologics, Inc. 17 RTI International 18 VG Life Sciences, Inc. 19 Pre-Eclampsia - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 A1M-001 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ALN-AGT - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 antithrombin alfa (recombinant) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 digoxin immune fab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PLX-PAD - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 VG-1177 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Pre-Eclampsia - Recent Pipeline Updates 44 Pre-Eclampsia - Dormant Projects 53 Pre-Eclampsia - Product Development Milestones 54 Featured News & Press Releases 54 Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia 54 Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells 54 Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia 56 Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies 56 Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia 57 Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting 59 Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1) 59 Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma's Treatment for Preeclampsia 60 Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia 60 Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia 61 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for Pre-Eclampsia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Pre-Eclampsia - Pipeline by A1M Pharma AB, H1 2016 13 Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 14 Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H1 2016 15 Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H1 2016 16 Pre-Eclampsia - Pipeline by rEVO Biologics, Inc., H1 2016 17 Pre-Eclampsia - Pipeline by RTI International, H1 2016 18 Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H1 2016 44 Pre-Eclampsia - Dormant Projects, H1 2016 53
List of Figures
Number of Products under Development for Pre-Eclampsia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and productRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.